drugset / Trial / NCT06537115

Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia

NCT06537115

Phase 4 Recruiting 450 enrolled Zhejiang Provincial People's Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

This clinical trial is a multicenter, single-blind, prospective, randomized controlled clinical application study. Subjects who met the trial criteria and signed the informed consent form were randomly divided into a control group, an experimental group 1, and an experimental group 2. After enrollment, the control group underwent a comprehensive assessment of their underlying conditions by professional physicians and received routine interventions, including basic nutritional intervention program guidance, progressive resistance exercise intervention program guidance, safety precautions, and symptomatic treatment for different complications, for a total intervention period of 24 weeks. The experimental group 1, in addition to the interventions provided to the control group, received whey protein powder supplementation for 12 weeks. The experimental group 2, on the other hand, received both whey protein powder and eldecalcitol supplementation on top of the interventions given to the control group, also for 12 weeks. The entire intervention period lasted for 24 weeks. Through regular general assessments, blood tests, measurements of muscle mass, muscle strength, and physical function, as well as analyses of negative adverse events, statistical methods were employed to evaluate the safety and efficacy of the comprehensive intervention methods for sarcopenia.

Timeline

Start
2024-06-16
Primary completion
2026-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Eldecalcitol Small molecule 0.75 ug Oral

Indications